Extended Data Fig. 1: PsA Antibiotic Sensitivity and Susceptibility. | Nature Medicine

Extended Data Fig. 1: PsA Antibiotic Sensitivity and Susceptibility.

From: Personalized inhaled bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis

Extended Data Fig. 1

MIC and antibiotic susceptibility results from sputum isolates taken pre- and post-therapy for (A) patient 1 (Npre=1, Npost=3, p = NA), (B) patient 2 (Npre=4, Npost=5, p=0.6905, 0.2063, 0.4444, 0.4444, >0.9999, 0.7222, 0.0476, 0.7619, 0.3968, 0.7857), (C) patient 3 (Npre=1, Npost=1, p=NA), (D) patient 4 (Npre=1, Npost=4, p=NA), (E) patient 5(Npre=2, Npost=4, p = 0.733, >0.9999, >0.9999, >0.9999,> 0.9999, >0.9999, >0.9999, 0.4667, 0.6667, 0.8667), (F) patient 6 (Npre=3, Npost=2, p=0.6000, 0.2000, 0.9000, 0.8000, 0.5000, 0.6000, 0.1000, 0.1000, 0.4000, 0.1000), (G) patient 7 (Npre=2, Npost=5, p=>0.9999, >0.9999, >0.9999, >0.9999, >0.9999, >0.9999, 0.1429, 0.1429, 0.3333, 0.0476), (H) patient 8 (Npre=3, Npost=1, p=NA), and (I) patient 9 (Npre=1, Npost=4, p=NA), to aztreonam (ATM), piperacillin/tazobactam (PIP/TAZ), cefepime (CEF), ceftazidime (CAZ), doripenem (DOM), meropenem (MEM), ciprofloxacin (CIP), levofloxacin (LEV), tobramycin (TOB) and colistin (COL). Antibiotic susceptibility determined to be resistant, intermediate, or sensitive according to CLSI. Data presented as mean +/- SD (Mann-Whitney test).

Back to article page